RYVU THERAPEUTICS ZY-40(9Y4)

Description: Ryvu Therapeutics S.A., a biotechnology company, engages in developing of small molecule therapies for treatment in oncology in Poland, rest of the European Union, and internationally. Its lead candidate, RVU120, is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat hematological malignancies, solid tumors, acute myeloid leukemia, myelodysplastic syndrome, and myelofibrosis. The company also develops SEL24/MEN1703, a dual PIM and FLT3 kinase inhibitor licensed to the Menarini Group that is in study start-up for Phase 2 clinical trial for the treatment of diffuse large b-cell lymphoma and acute myeloid leukemia. In addition, its early pipeline candidates include candidates in the areas of kinases, synthetic lethality, and immuno-oncology. The company has collaborations with BioNTech SE to advance small molecule programs to target immune modulation in cancer and other disease areas; Exelixis Inc. for the development of targeted therapies based on Ryvu's STING agonist technology. The company was formerly known as Selvita S.A. and changed its name to Ryvu Therapeutics S.A. in October 2019. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.

---

Keywords: Biotechnology Cancer Disease Solid Tumors Acute Myeloid Leukemia Protein Kinase Inhibitor Hematological Malignancies Targeted Therapy Myelodysplastic Syndrome Tyrosine Kinase Receptors Small Molecule Therapies Myelofibrosis Bemcentinib Diffuse Large B Cell Lymphoma Cd135 Flt3 Cyclin Dependent Kinase 8 Lestaurtinib

---

Home Page: ryvu.com

Leona Henryka Sternbacha 2
Kraków, 30-394
Poland
Phone: 48 12 314 0200

---

Officers

Exchange: F

Country: DE : Germany

Currency: Euro (€)